Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — Kyowa Hakko Kirin — H1 2008 Earnings Presentation
31 slides from Kyowa Kirin's earnings presentation, Oct 30, 2008
Slide 1: Fiscal 2008 First Half Results
Kyowa Hakko Kirin Co., Co Ltd Fiscal 2008 First Half Results October 30, 2008 President and Chief Executive Officer Yuzuru Matsuda Statements on results, forecasts and R&D status contained in this presentation represent judgments based on information available at the current time. Actual results may
Slide 2: Business structure (from October 1, 2008)
z Business structure (200810.1 ~) Kirin Holdings Sepa Kirin Kirin Merc Othe Kirrin Food- com mpanies n Brewery n Beverage er business cian arate servic Kyowa Hakko Food-Tech Kirin Co., Ltd. ses ce Other subsidiaries SPECIA KYOWA CHEMIC KYOWA KYOWA Business integration 2009.4.1 Launched Kirin Kyowa F
Slide 3: Outline of Fiscal 2008 first half results
z Outline of Fiscal 2008 first half results Operating Recurring (¥bn) Net sales Net income income income FY08 H1 247.7 29.1 30.3 8.2 +55.1 +10.9 +12.2 -2.7 Change (+28 6%) (+28.6%) (+59 8%) (+59.8%) (+67 9%) (+67.9%) (-25 0%) (-25.0%) FY07 H1 192.6 18.2 18.0 11.0 z Pharmaceuticals Sales and profits
Slide 4: Segmental sales changes: Fiscal 2008 interim
z Segmental sales changes: Fiscal 2008 interim Sales breakdown Pharmaceuticals: + ¥39.8bn Bio-Chemicals: + ¥1.9bn September 2007 1,100 465 12% 1,000 450 10% 33% 900 435 800 420 700 405 24% 600 390 21% 500 375 Pharmaceuticals Ph ti l Bio-Chemicals Bi Ch i l Chemicals Food 360 Other 400 300 345 2007
Slide 5: Segmental operating income changes: Fiscal 2008 interim
z Segmental operating income changes: Fiscal 2008 interim Operating income breakdown Pharmaceuticals: + ¥9.9bn Bio-Chemicals: + ¥1.1bn September 2007 53 200 50 180 47 160 4% 2% 44 140 18% 41 54% 120 22% 38 100 35 80 32 60 29 Pharmaceuticals Bio-Chemicals Chemicals 40 26 Food Other 20 23 0 20 2007/
Slide 6: Pharmaceuticals
z Pharmaceuticals (Comparison of simple sum of both company’s FY07 and FY08 results) FY 2007 Interim FY 2008 (¥bn) (Sum of two Change Interim companies) Net sales 103.5 108.7 +5.1 Operating income 16.1 24.0 +7.9 R&D expenses 24.8 23.0 -1.8 *Figures for FY 2008 Interim operating income is based on be
Slide 7: Sales of core pharmaceutical products
z Sales of core pharmaceutical products Reference: Reference: Full year Full year (¥ bn) 2007/9 2008/9 forecast forecast (As of July 31) (Revised) NESP/ESPO 22 5 22.5 21 3 21.3 46 8 46.8 43 0 43.0 Coniel 13.2 11.6 22.8 22.9 All l k Allelock 95 9.5 96 9.6 23 3 23.3 23 1 23.1 Patanol 0.8 1.4 5.0 4.9 G
Slide 8: Bio-Chemicals
z Bio Bio--Chemicals (¥bn) FY06 H1 FY07 H1 FY08 H1 Change from FY07 H1 Net sales 33 3 33.3 43 8 43.8 45 7 45.7 +1 9 +1.9 Operating 1.5 4.0 5.2 +1.1 i n c o m e Sales Sa es and a d profits p o ts up due to growth g o t in a amino o ac acids ds for o intravenous t a e ous a and d co continued t ued gr
Slide 9: Fiscal 2008 full-year forecasts (consolidated)
z Fiscal 2008 full- full-year forecasts (consolidated) Operating Recurring (¥bn) Net sales Net income income income FY 2008 forecast 490 0 490.0 50 0 50.0 50 0 50.0 17 0 17.0 (Compared to forecast announced April 2008） （--） (-12.3%） (-10.7%) (-39.3%) FY 2008 forecast 490 0 490.0 57 0 57.0 56 0 56.0
Slide 10: Pharmaceuticals
KYOWA KIRIN Pharmaceuticals
Slide 11: R&D pipeline (As of October 2008)
z R&D pipeline (As of October 2008) Kyowa Hakko Kirin As of October 30, 2008 Code Name Stage In-house Category Indication Formulation OR Remarks Product Name Japan Other countries Licensed ☆ Long-acting erythropoiesis stimulating protein. Anemia KRN321 NESP Phase III Injection Kirin-Amgen Sales for
Slide 12: R&D pipeline (As of October 2008)
z R&D pipeline (As of October 2008) Code Name Stage In-house Category Indication Formulation OR Remarks Product Name Japan Other countries Licensed PB94 Filed in China PHOSBLOCK Hyperphosphatemia Oral Chugai Launched in Japan (June 2008) (RENEGAL) Kidney Phase II in ☆Anemia (for CKD patients not ☆ L
Slide 13: Antibody pharmaceutical pipeline (As of October 2008)
z Antibody pharmaceutical pipeline (As of October 2008) Overview of Development Pipeline Therapeutic p Pre clinical Pre-clinical Ph Phase-1 1 Ph Phase-2 2 area KW-0761 KW-2871 ((CCR4)) ((GD3)) Cancer Life Science Pharmaceuticals KRN330 7 antibodies KW-0761 BIW-8405 Immunological （of which 5 are (CCR
Slide 14: POTELLIGENT Technology-related licensing
z POTELLIGENT ® Technology echnology--related licensing (As of October 2008) Technology license Joint R&D CSL CaloBios Product level alliance Out-licensing In-licensing 13
Slide 15: Progress in licensing-out (As of October 2008)
z Progress in licensing- licensing-out (As of October 2008) Phase Partner Pre-clinical Remarks Ⅰ Ⅱ Ⅲ Anticancer A ti ((acute t CEP-701 Cephalon myelocytic leukemia) KW-3902 Merck Congestive heart failure, (MK-7418) (NovaCardia) Renal failure LY 2523355 Mitotic Kinesin Eg5 Eli Lilly (Eg5 inhibitor) i
Slide 16: Progress in licensing-in (As of October 2008)
z Progress in licensing- licensing-in (As of October 2008) Phase Partner Pre-clinical Remarks Ⅰ Ⅱ Ⅲ Anti-Parkinson’s disease KW 6500 KW-6500 Britannia* Britannia (injection) Inflammatory bowel disease Zeria Asacol (Crohn’s disease) Pharmaceuticals Application filed for ulcerative colitis ARQ197 ArQu
Slide 17: KW-0761 Out-licensing to Amgen
z KW KW--0761 Out- Out-licensing Out-licensed to Amgen Out-licensing O t licensing conditions: conditions z Granted exclusive license to develop and sell worldwide, except in Japan, Korea, China and Taiwan z Applies to all applications except anticancer zRegarding rights to anticancer agents, Am
Slide 18: Reorganization of US subsidiary structure
z Reorganization of US subsidiary structure (Scheduled for January 1, 2009) Kirin Holdings Kirin Holdings Kyowa Hakko Kirin Kyowa Hakko Kirin Kyowa Hakko Kirin America, Inc. Kyowa Hakko Kirin America, Inc. Kyowa Hakko Kirin Kyowa Hakko Kirin BioWa KPI* KPUSA* HMT* BioWa Pharma, Inc. California, Inc.
Slide 19: Kyowa Hakko Kirin antibody business strategy
z Kyowa Hakko Kirin antibody business strategy KM-Mouse® Manufacturing Hematech of EXPOC OC POTELLIGENT® Technology T h l G CS & G-CSF Technology COMPLEGENTTM Technology Erythropoietin Discover Produce and Non-clinical Clinical and assess develop Manufacture trials trials antigen ti antibodies tib d
Slide 20: Development stages of antibody businesses
z Development stages of antibody businesses Technology & Early-stage Early- & late-stage Late-stage & Fully integrated pipeline provider developer developer marketing biotech & pharma Core technology Core technology Core technology & & & Development of Development of Development of candidate candida
Slide 21: Integration of the food businesses
Integration of the food businesses 20
Slide 22: Integration of the food businesses
z Integration of the food busineses K Kyowa H Hakko kk FFood dSSpecialties i lti Co., C Ltd Ltd. Ki i Food-Tech Kirin F d T h Company C Net sales ¥43.3 bn ¥27.2 bn Capital ¥3.0 bn ¥5.0 bn Staff 586 261 Business Manufacturing and sale of seasonings and bakery Manufacture and sale of seasonings for pr
Slide 23: Integration of the food businesses: steps and structure
z Integration of the food businesses April 1, 2009 ～ December 31, 2010 January 1, 2011 Kirin Holdings Company Kirin Holdings Company Kyowa Hakko Kirin Co. Ltd. Kirin Kyowa Foods Company Kyowa Hakko Kirin Co. Ltd. Kirin Kyowa Foods Company KYOWA HAKK KYOWA HAKKO CHEMICAL CO., KYOWA HAKKO BIO CO.., LT
Slide 24: APPENDIX
KYOWA KIRIN APPENDIX 23
Slide 25: Pharmaceuticals: Major factors effecting results
z Pharmaceuticals: Major factors effecting results (All listed factors are on a non non-consolidated consolidated basis unless otherwise noted) FY 2007 H1 Net sales FY 2008 H1 ¥68.9 bn +¥39.8 bn ¥108.7 bn Consolidation of Kirin Pharma Positive factors Onetime contract payment from Amgen Launched Cov
Slide 26: Bio-Chemicals: Major factors effecting results
z Bio Bio--Chemicals : Major factors effecting results (All listed factors are on a non-consolidated basis unless otherwise noted) FY 2007 H1 Net sales FY 2008 H1 ¥43.8 bn +¥1.9 bn ¥45.7 bn Positive factors Increased bulk sales of raw materials for pharmaceutical and industrial use Increased mail- m
Slide 27: Chemicals
z Chemicals Change from (¥bn) FY06 H1 FY07 H1 FY08 H1 FY07 H1 Net sales 45 8 45.8 51 0 51.0 57 2 57.2 +6 1 +6.1 Operating 1.6 3.2 2.9 -0.3 i n c o m e Price revisions were implemented against a background of higher raw material and fuel prices z Domestic: Sales increased with the implementation of p
Slide 28: Chemicals: Major factors effecting results
z Chemicals: Major factors effecting results (All listed factors are on a non-consolidated basis unless otherwise noted) FY 2007 H1 Net sales FY 2008 H1 ¥51.0 bn +¥6.1 bn ¥57.2 bn Positive factors (Domestic) Price revisions of basic chemical products (Exports) Firm market, growth in specialty chemic
Slide 29: Food
z Food Change from (¥bn) FY06 H1 FY07 H1 FY08 H1 FY07 H1 Net sales 20.9 20.9 20.8 -0.1 Operating 08 0.8 06 0.6 05 0.5 -0.1 01 i n c o m e Achieved results in line with as p previous fiscal yyear amidst an environment of high g fuel and raw material prices. z Natural seasonings: Sales of fermented se
Slide 30: Food: Major factors effecting results
z Food: Major factors effecting results (All listed factors are on a non-consolidated basis unless otherwise noted) FY 2007 H1 Net sales FY 2008 H1 ¥20.9 bn -¥0.1 bn ¥20.8 bn Positive factors Increased sales volumes of fermented seasonings and Umami seasonings Negative factors Decreased sales volume
Slide 31: KYOWA KIRIN
KYOWA KIRIN KYOWA KIRIN